Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner
- 26 October 2007
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 57 (6) , 813-821
Abstract
Naturally occurring regulatory T (TR) cells suppress autoreactive T cells whereas adaptive TR cells, induced in the periphery, play an important role in chronic viral diseases and cancer. Several studies indicate that cyclooxygenase (COX) inhibitors prevent cancer development of colon adenomas and delay disease progression in patients with colorectal cancer (CRC). We have shown that adaptive TR cells express COX-2 and produce PGE2 that suppress effector T cells in a manner that is reversed by COX-inhibitors.Keywords
This publication has 40 references indexed in Scilit:
- A Large Cohort Study of Long-Term Daily Use of Adult-Strength Aspirin and Cancer IncidenceJNCI: Journal of the National Cancer Institute, 2007
- Transient regulatory T-cells: A state attained by all activated human T-cellsClinical Immunology, 2007
- NSAIDs and Cancer Prevention: Targets Downstream of COX-2Annual Review of Medicine, 2007
- CD4+CD25+FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal CancerPLOS ONE, 2006
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- Celecoxib for the Prevention of Sporadic Colorectal AdenomasNew England Journal of Medicine, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Immunosuppressive networks in the tumour environment and their therapeutic relevanceNature Reviews Cancer, 2005
- Smoldering and polarized inflammation in the initiation and promotion of malignant diseaseCancer Cell, 2005
- Inflammation and cancerNature, 2002